<DOC>
	<DOCNO>NCT00274586</DOCNO>
	<brief_summary>Tolerability four week treatment AggrenoxÂ® modify release capsule b.i.d , compare reduce dose first two week treatment double-blind , randomize control parallel group comparison trial among Taiwanese patient previous TIA 's ischemic stroke.To monitor frequency intensity headache safety parameter among Taiwanese patient previous TIA 's ischemic stroke give Aggrenox use titration scheme</brief_summary>
	<brief_title>Headache Study Compare Aggrenox Full Dose Reduced Dose</brief_title>
	<detailed_description>The major objective study evaluate tolerance headache safety Taiwan Taiwanese patient receive two different dose regimen Aggrenox Aggrenox placebo . The first group start placebo day 1-4 , daily dose day 5-14 , follow b.i.d treatment 15-28 day . This group also receive match placebo morning one Aggrenox capsule even day 5-14 . It enable reduce perception dipyridamole-associated headache . The second group receive placebo twice daily day 1-4 , medication twice daily remain course . The third group receive placebo twice daily whole course . Study Hypothesis : NULL AND ALTERNATIVE HYPOTHESES From subject diary , ask frequent side effect observe ESPS2 trial , cumulative headache ( intensity x frequency ) per day base first three day treatment period defines primary endpoint . I : H0 : Median cumulative headache equal treatment group vs. HA : Median cumulative headache equal treatment group II : H0 : Median cumulative headache low dose regimen ? Median cumulative headache regular dose vs. HA : Median cumulative headache low dose regimen &lt; Median cumulative headache regular dose Comparison ( ) : Compare Aggrenox full dose , reduce dose placebo</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Aspirin , Dipyridamole Drug Combination</mesh_term>
	<criteria>1 . 20 year old . 2 . History TIA complete ischemic stroke 3 . Signed informed consent . 4 . Patient score &lt; 2 modify Rankin 's Classification Neurological Status . 1 . Patients know suspected prior intracranial haemorrhage history brain injury brain tumor . 2 . Disorders related syncope , drop attack , congenital vascular malformation , aneurysm , angioma , epilepsy , psychiatric disorder . 3 . Peptic ulcer gastrointestinal bleeding within 6 month . 4 . History hypersensitivity intolerance study drug aspirin . 5 . Experienced habitual headache ( form ) within past 3 month . 6 . History dysphasia , dysphagia , dementia , unconsciousness . 7 . Patients currently take medication know cause headache ( e.g. , nitrate ) . 8 . Patients deteriorate angina , subvalvular aortic stenosis hemodynamic liability ( e.g. , conjunction recent myocardial infarction ) . 9 . Uncontrolled hypertension ( SBP &gt; 220 mmHg , DBP &gt; 120 mmHg ) lifethreatening disease . 10 . Any significant disorder , chronic renal failure ( serum creatinine &gt; 2.0 mg/dl ) , neoplasia . 11 . SGPT , SGOT value great 2 time upper normal limit . 12 . Insulin dependent diabetes mellitus poorly control noninsulin dependent diabetes mellitus ( AC sugar &gt; 300 mg/dl ) . 13 . Use anticoagulant , anticoagulated agent NSAIDsS . 14 . History alcohol and/or drug abuse . 15 . Having participated investigational drug study within 3 month prior study entry . 16 . Pregnant lactate woman woman childbearing potential practicing reliable birth control . 17 . The patient take methylxanthinecontaining drink food ( coffee , black tea , cola , energy drink , etc . ) 4 cup coffee 's equivalent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>